POST Online Media Lite Edition


FTC approves final order imposing conditions on AbbVie’s acquisition of Allergan

Christian Fernsby |
The Federal Trade Commission has approved a final order settling charges that AbbVie’s $63 billion acquisition of Allergan would violate federal antitrust law.

Article continues below

Topics: FTC    ABBVIE    ALLERGAN   

According to the complaint, which was first announced in May 2020, the proposed acquisition would likely harm current competition in the market for treatment of exocrine pancreatic insufficiency, or EPI, a condition that results in the inability to digest food properly; and future competition in the market for IL-23 inhibitors, a class of drug that treats both moderate-to-severe Crohn’s disease and moderate-to-severe ulcerative colitis.

The final order requires AbbVie and Allergan to divest to Nestlé, S.A. Allergan’s Zenpep and Viokase, which are currently sold to treat EPI.

AbbVie and Allergan also are required to divest to AstraZeneca plc. Allergan’s rights and assets related to brazikumab – an IL-23 inhibitor that is in development to treat moderate-to-severe Crohn’s disease and ulcerative colitis.

What to read next

Allergan rejects Valeant's proposal
Tronox to vigorously fight FTC lawsuit against Cristal acquisition
Actavis to change name to Allergan, selling $8.4bn in shares to finance takeover